| Outcome Measures: |
Primary: Safety Profile: Number of Subjects Experiencing at Least 1 Adverse Event, Safety Profile: Number of subjects who experienced at least 1 adverse event in each arm, baseline through week 12 | Secondary: Number of Subjects Achieving Clinical Success, Summary of the Number of Subjects Achieving Clinical Success During the 12-Week Study Period - Hemoglobin between 10.5 g/dL and 14.0 g/dL, Inclusive, TSAT between 20% and 50%, Inclusive, and Stable EPO Dosing (±25% of Baseline Dose), anytime during the 12 week post-baseline period|Percentage (%) of Subjects Achieving Clinical Success, Summary of the Percentage (%) of Subjects Achieving Clinical Success During the 12-Week Study Period - Hemoglobin between 10.5 g/dL and 14.0 g/dL, Inclusive, TSAT between 20% and 50%, Inclusive, and stable EPO Dosing (±25% of Baseline Dose), anytime during the 12 week post-baseline period|Number of Subjects With Hemoglobin Between 10.5 g/dL and 14.0 g/dL, Inclusive, Summary of the Number of Subjects with Hemoglobin between 10.5 g/dL and 14.0 g/dL, Inclusive, anytime during the 12-week post-baseline period|Percentage (%) of Subjects With Hemoglobin Between 10.5 g/dL and 14.0 g/dL, Inclusive, Summary of the Percentage (%) of Subjects with Hemoglobin Between 10.5 g/dL and 14.0 g/dL, Inclusive, anytime during the 12 week post-baseline period|Proportion of Subjects With Transferrin Saturation (TSAT) Between 20% and 50%, Inclusive, Summary of the Proportion of Subjects with transferrin saturation (TSAT) between 20% and 50%, Inclusive, anytime during the 12 week post-baseline period|Percentage (%) of Subjects With TSAT Between 20% and 50%, Inclusive, Summary of the Percentage (%) of Subjects with TSAT between 20% and 50%, Inclusive, anytime during the 12 week post-baseline period|Proportion of Subjects With Stable Erythropoietin (EPO) Dosing or a Decrease >25% in EPO Dose From Baseline, Summary of the Proportion of Subjects with Stable erythropoietin (EPO) Dosing or a Decrease \>25% in EPO dose from Baseline, anytime during the 12 week post-baseline period|Percentage (%) of Subjects With Stable EPO Dosing or a Decrease >25% in EPO Dose From Baseline, Summary of the Percentage (%) of Subjects with Stable EPO Dosing or a Decrease \>25% in EPO Dose from Baseline, anytime during the 12 week post-baseline period
|
